Professional Challenges for United States Hematology/Oncology Trainees during COVID-19.


Journal

Cancer investigation
ISSN: 1532-4192
Titre abrégé: Cancer Invest
Pays: England
ID NLM: 8307154

Informations de publication

Date de publication:
Jul 2023
Historique:
medline: 1 8 2023
pubmed: 6 4 2023
entrez: 5 4 2023
Statut: ppublish

Résumé

COVID-19 has been devastating for patients with cancer. In this commentary, we chronicle the pandemic's downstream impacts on United States hematology/oncology trainees in terms of professional development and career advancement. These include loss of access to clinical electives and protocol workshops, delays in research approval and execution, mentor shortages due to academic burnout, and obstacles with career transitions (most notably the post-fellowship job search). While certain silver linings from the pandemic have undoubtedly emerged, continued progress against COVID-19 will be essential to fully overcome the professional challenges it has created for the future hematology/oncology workforce.

Identifiants

pubmed: 37017426
doi: 10.1080/07357907.2023.2199216
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

539-547

Auteurs

Rahul Banerjee (R)

Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Samuel A Kareff (SA)

Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, Florida, USA.

Yan Leyfman (Y)

Department of Medicine, Icahn School of Medicine at Mount Sinai South Nassau, Rockville Centre, New York, USA.

Natasha Dhawan (N)

Department of Medicine, Section of Hematology and Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.

Lindsay R Hammons (LR)

Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Aakash Desai (A)

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.

Mazie Tsang (M)

Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, USA.

Ana I Velazquez (AI)

Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.

Amanda Nizam (A)

Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH